



Patent  
270/234

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: ) Group Art Unit: 2882  
Yoshihiro Takai et al. ) Examiner: Not Yet Assigned  
Serial No.: 10/037,477 )  
Filed: January 2, 2002 )  
For: METHOD AND APPARATUS FOR )  
IRRADIATING A TARGET )

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

RECEIVED  
APR - 1 2004  
TECHNOLOGY CENTER 3700

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

August 02, 2002  
Date of Deposit

Angelica Jaquez  
Name of Person Mailing Paper

Angelica Jaquez  
Signature of Person Mailing Paper




RECEIVED  
APR - 1 2004  
TECHNOLOGY CENTER 3700

Please acknowledge receipt of the following by affixing hereon the Patent and Trademark Office date stamp and returning this card to our office.

Applicant: Yoshihiro Takai et al.  
Serial No.: 10/037,477  
For: METHOD AND APPARATUS FOR IRRADIATING A  
TARGET  
Filed: January 2, 2002

#### INFORMATION DISCLOSURE STATEMENT

Attorney(s): Ziye J. Zhou  
Docket No.: 270/234  
Client Name: Varian Medical Systems, Inc.  
Date of Deposit: August 2, 2002  
Enclosure(s): Information Disclosure Statement (3 pp.); Form PTO-1449 (1 p.); References AA-AH; and Return



**INFORMATION DISCLOSURE STATEMENT FILING PROVISION:**

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.

This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

The fee due under 37 CFR § 1.17(p) is submitted herewith.

A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.

This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

**STATEMENT UNDER 37 CFR § 1.97(e):**

Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**

- A check in the amount of \_\_\_\_\_ is enclosed for the above fee(s).
- Please charge \_\_\_\_\_ to Deposit Account No. 12-2475 for the above fee(s).

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. 12-2475.

Respectfully submitted,  
**LYON & LYON LLP**

By: 

Ziye J. Zhou  
Reg. No. 41,423

Dated: August 2, 2002




22249

**LYON & LYON LLP**  
633 W. Fifth Street, Suite 4700  
Los Angeles, CA 90071

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

MAR 2 2004

ATTY. DOCKET NO.  
270/234SERIAL NO.  
10/037,477APPLICANT:  
Yoshihiro Takai et al.FILING DATE:  
January 2, 2002GROUP:  
2882

## PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
AA	5,727,554	03/17/98	Kalend et al.	128	653.1	09/19/96
AB	5,823,192	10/20/98	Kalend et al.	128	845	07/31/96
AC	6,020,159	02/01/00	Black et al.	435	69.1	08/04/97
AD	6,138,302	10/31/00	Sashin et al.	5	600	11/10/98
AE	6,307,914 B1	10/23/01	Kunieda et al.	378	65	12/01/99

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

AF	B.J. Lopresti, et al., "Implementation and Performance of an Optical Motion Tracking System for High Resolution Brain PET Imaging", <i>IEEE Transactions on Nuclear Science</i> , Vol. 46, No. 6, December 1999; pp. 2059-2067
AG	P.J Keall, et al., "Motion adaptive x-ray therapy: a feasibility study", <i>Physics in Medicine Biology</i> , 46 (2001) 1-10
AH	Paul Keall, "4D IMRT: Imaging, Planning and Delivery", January 31, 2001, pp. 1-53

EXAMINER:  
Not Yet Assigned

DATE CONSIDERED:

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609;  
Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant



Please acknowledge receipt of the following by affixing hereon the Patent and Trademark Office date stamp and returning this card to our office.

Applicant: Yoshihiro Takai et al.  
Serial No.: 10/037,477  
For: METHOD AND APPARATUS FOR IRRADIATING A  
TARGET  
Filed: January 2, 2002

### SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Attorney(s): Peter C. Mei  
Docket No.: 270/234  
Client Name: Varian Medical Systems, Inc.  
Date of Deposit: August 27, 2002  
Enclosure(s): Supplemental Information Disclosure Statement (2 pp.); PTO  
1449 (1 p.); References AA-AK; and Return Postcard.

RECEIVED

APR - 1 2004

TECHNOLOGY CENTER 3700

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re the Application of:

Group Art Unit: 2882

Yoshihiro Takai et al.

Examiner: Not Yet Assigned

Serial No.: 10/037,477

Filed: January 2, 2002

For: METHOD AND APPARATUS FOR  
IRRADIATING A TARGET

RECEIVED

APR - 1 2004

TECHNOLOGY CENTER 3700

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO-1449 and copies are enclosed for the convenience of the Examiner.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

**INFORMATION DISCLOSURE STATEMENT FILING PROVISION:**

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d); or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

August 27, 2002  
Date of Deposit

Angelica Jaquez  
Name of Person Mailing Paper  
Signature of Person Mailing Paper

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.

This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

The fee due under 37 CFR § 1.17(p) is submitted herewith.

A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.

This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

**STATEMENT UNDER 37 CFR § 1.97(e):**

Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.

No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**

The Commissioner is authorized to charge any fees required by the filing of these papers, and to credit any overpayment to Lyon & Lyon's Deposit Account No. **12-2475**.

Respectfully submitted,  
**LYON & LYON LLP**

By:

Ziye J. Zhou  
Reg. No. 41,423

Dated: August 27, 2002



22249

**LYON & LYON LLP**  
633 W. Fifth Street, Suite 4700  
Los Angeles, CA 90071

**LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

ATTY. DOCKET NO.  
270/234

SERIAL NO.  
10/037,477

APPLICANT:  
Yoshihiro Takai et al.

FILING DATE:  
January 2, 2002

GROUP:  
2882

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
AA	5,207,223	5/4/93	Adler	128	653.1	10/19/90
AB	5,427,097	6/27/95	Depp	128	653.1	12/10/92
AC	6,144,875	11/7/00	Schweikard et al.	600	427	3/16/99
AD	6,222,901	4/24/01	Meulenbrugge et al.	378	19	3/12/99

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**

AE	Yonesaka A. et al., "Application of real-time tracking radiation therapy (RTRT) system for the treatment of spinal and paraspinal diseases"; <i>J. Radiat Oncol. Biol. Phys.</i> , 2001; 51 (3S1): Abstract No. 44., PMID: 14; 2 pp.
AF	Jolesz, Ferenc A., M.D., "IMAGE-GUIDED PROCEDURES AND THE OPERATING ROOM OF THE FUTURE"; <i>Brigham and Women's Hospital, Harvard Medical School</i> ; pp. 1-23.
AG	Shimizu, S., et al., "Fluoroscopic Real-Time Tumor-Tracking Radiation Treatment (RTRT) Can Reduce Internal Margin (IM) and Set-up Margin (SM) of Planning Target Volume (PTV) for Lung Tumors; 2 pp.
AH	Kitamura, K., et al., "Migration of the Internal Fiducial Gold Marker Implanted into Prostate and Liver treated with Real-Time Tumor-Tracking Radiation Treatment (RTRT)", <i>Hokkaido University School of Medicine, Sapporo, Japan</i> ; 2 pp.
AI	Kitamura, Kei et al.; "3D INTRA-FRACTIONAL MOVEMENT OF PROSTATE MEASURED DURING REAL-TIME TUMOR TRACKING RADIATION THERAPY [RTRT] IN SUPINE AND PRONE TREATMENT POSITIONS"; <i>Department of Radiology and Urology, Hokkaido University School of Medicine</i> ; 15 pp.
AJ	Fujita K., "Three-dimensional conformal set-up of prostate cancer by adjustment of actual clinical target volume (CTV) to virtual CTV using three fiducial markers and fluoroscopic real-time tracking system.", <i>J. Radiat. Oncol. Biol. Phys.</i> , 2001; 51 (3S1): Abstract No. 2303, PMID: 16; 2 pp
AK	Benedict, Stanley H., "Looking Into Patient Positioning and Organ Motion", <i>VCU Health System</i> , pp. 1-10.

**RECEIVED**

APR - 1 2004

TECHNOLOGY CENTER 3700

**EXAMINER:**  
Not Yet Assigned

**DATE CONSIDERED:**

**EXAMINER:** Initial if reference is considered, whether or not citation is in conformance with MPEP 609;  
Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant



RECEIVED

APR - 1 2004

TECHNOLOGY CENTER 3700

First Class Mail  
Date Mailed March 4, 2003 Due Date: \*N/A\*  
Applicant(s): Yoshihiro Takai et al. Atty. Docket 270234; 18721-7053  
Title: METHOD AND APPARATUS FOR IRRADIATING A TARGET  
Serial No.: 10/637,477 Filing Date: January 2, 2002


---

Commissioner for Patents  
Washington, DC 20231

SIR: Please place the U.S. Patent and Trademark Office date stamp hereon to acknowledge receipt of the following:

1. Second Supplemental Information Disclosure Statement with Certificate of Mailing (3 pages)
2. Forms PTO/SB/08A&B (2 pages)
3. Cited References (20)
4. Return Receipt Postcard

52099722.1/2018721-2187217053



CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

[X] I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit: 3/4/03 MAR 22 2004

Signature of Person Certifying: Carolyn Tobias  
Printed Name: Carolyn Tobias

U.S. PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: ) Group Art Unit: 2882  
Yoshihiro Takai et al. )  
Serial No.: 10/037,477 )  
Filed: January 2, 2002 )  
For: METHOD AND APPARATUS FOR ) Examiner: Not yet assigned  
IRRADIATING A TARGET )

RECEIVED  
APR - 1 2004  
TECHNOLOGY CENTER 3700

SECOND SUPPLEMENTAL  
INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 CFR §§ 1.97 and 1.98, the items identified in this Information Disclosure Statement ("IDS") are brought to the attention of the Office. The items are listed on the attached form PTO/SB/08A. Copies of the items listed are enclosed herewith.

The items identified in this IDS may or may not be "material" pursuant to 37 CFR § 1.56. The submission thereof by Applicants is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as "prior art" under 35 USC § 102 with respect to this invention unless specifically designated by Applicants as such.

**INFORMATION DISCLOSURE STATEMENT FILING PROVISION:**

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d) or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.

This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office Action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

The fee due under 37 CFR § 1.17(p) is submitted herewith.

A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.

This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

This IDS is being submitted under 37 CFR § 1.97(i), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee.

**STATEMENT UNDER 37 CFR § 1.97(e):**

- Each item contained in this IDS was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**

- A check in the amount of \_\_\_\_\_ is enclosed for the above fee(s).
- The Commissioner is authorized to credit any overpayment and to charge any underpayment to Bingham McCutchen's Deposit Account No. 50-2518, referencing billing No. 18721-7053, for any fees required by the filing of these papers.

Respectfully submitted,

Dated: 3/4/03

By:

  
Gerald Chan  
Reg. No. 51,541

BINGHAM McCUTCHEN LLP  
Three Embarcadero, Suite 1800  
San Francisco, CA 94111-4067  
Telephone: (650) 849-4904  
Telefax: (650) 849-4800

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

## SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	10/037,477
Filing Date	January 2, 2002
First Named Inventor	Yoshihiro Takai
Art Unit	2882
Examiner Name	Not yet assigned
Attorney Docket No.	270/234; 18721-7053

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published
	1	Balter, J. M. et al., "Daily targeting of intrahepatic tumors for radiotherapy," <i>Int J Radiat Oncol Biol Phys</i> , 2002, Jan 1:52(1), pp. 266-71
	2	Cho, P.S. et al. "Cone-beam CT for radiotherapy applications," <i>Phys Med Biol</i> 1995;40: pp. 1863-1883.
	3	Drake, D.G. et al. "Characterization of a fluoroscopic imaging system for kilovoltage and megavoltage radiography," <i>Med Phys</i> 2000;27: pp. 898-905.
	4	Fahrig, R. et al., "Three-dimensional computed tomographic reconstruction using a C-arm mounted XRII: Imagebased correction of gantry motion non-idealities," <i>Med Phys</i> 2000;27:30-38.
	5	Feldkamp, L.A. et al. "Practical cone-beam algorithm," <i>J Opt Soc Am A</i> 1984;1: pp. 612-619.
	6	Groh, B.A. et al. "A performance comparison of flat-panel imager-based MV and kV conebeam CT," <i>Med Phys</i> 2002;29: pp. 967-975.
	7	Jaffray, D.A. et al. "A radiographic and tomographic imaging system integrated into a medical linear accelerator for localization of bone and soft-tissue targets," <i>Int J Radiat Oncol Biol Phys</i> 1999;45: pp. 773-789.
	8	Jaffray, D.A. et al. "Cone-beam computed tomography with a flat-panel imager: Initial performance characterization," <i>Med Phys</i> 2000;27: pp.1311-23.
	9	Keall, P. J. et al., "[Abstract] Motion Adaptive X-ray Therapy: A feasibility study," <i>3rd Annual IMRT Symposium ABSTRACTS</i> , Chicago 2000 World Congress, July 24, 2000, Sheraton Chicago, Chicago, Illinois.
	10	Keall, P. J. et al., "[Presentation] Motion Adaptive X-Ray Therapy; A Feasibility Study," Medical College of Virginia Hospitals, Virginia Commonwealth University.
	11	Midgley, S., et al. "A feasibility study for megavoltage cone beam CT using commercial EPID," <i>Phys Med Biol</i> 1998;43: pp. 155-169.

Examiner's Signature

Date Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MAR 22 2004

Substitute for form 1449A-PTO

## SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANTS

*(use as many sheets as necessary)*

Sheet

2

of

2

*Complete if Known*

Application Number	10/037,477
Filing Date	January 2, 2002
First Named Inventor	Yoshihiro Takai
Art Unit	2882
Examiner Name	Not yet assigned
Attorney Docket No.	270/234; 18721-7053

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

12	Mosleh-Shirazi, M.A. et al. "A cone-beam megavoltage CT scanner for treatment verification in conformal radiotherapy," <i>Radiother Oncol</i> 1998; 48: pp. 319–328.
13	Nakagawa, K. et al. "Megavoltage CT-assisted stereotactic radiosurgery for thoracic tumors: Original research in the treatment of thoracic neoplasms," <i>Int J Radiat Oncol Biol Phys</i> 2000; pp. 48:449–457.
14	Pisani, L. et al. "Setup error in radiotherapy: On-line correction using electronic kilovoltage and megavoltage radiographs," <i>Int J Radiat Oncol Biol Phys</i> 2000; 47: pp. 825–839.
15	Ruchala, K.J. et al. "Megavoltage CT on a tomotherapy system," <i>Phys Med Biol</i> 1999; 44: pp. 2597–2621.
16	Siewerdsen, J.H. et al. "Cone-beam computed tomography with a flat-panel imager: Magnitude and effects of x-ray scatter," <i>Med Phys</i> 2001;28: pp. 220–231.
17	Siewerdsen, J.H., et al. "Optimization of x-ray imaging geometry (with specific application to flat-panel cone-beam computed tomography)," <i>Med Phys</i> 2000;27: pp. 1903–1914.
18	Swindell, W. et al., "Computed tomography with a linear accelerator with radiotherapy application," <i>Med Phys</i> , 10, pp. 416–420.
19	Uematsu, M. et al. "A dual computed tomography linear accelerator unit for stereotactic radiation therapy: A new approach without cranially fixated stereotactic frames," <i>Int J Radiat Oncol Biol Phys</i> 1996;35: pp. 587–592.
20	Uematsu, M. et al. "Intrafractional tumor position stability during computed tomography (CT)-guided frameless stereotactic radiation therapy for lung or liver cancers with a fusion of CT and linear accelerator (FOCAL) unit," <i>Int J Radiat Oncol Biol Phys</i> 2000;48: pp.443–448.

Examiner's Signature	Date Considered
----------------------	-----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



First Class Mail

Date Mailed

March 17, 2003

Due Date: \*\*

Atty. Docket 270/234; 18721-7053  
(PCM:ct)

Applicant(s):

Yoshihiro Takai, et al.

Title:

METHOD AND APPARATUS FOR IRRADIATING A TARGET

Serial No.:

10/037,477


Filing Date: January 2, 2002

Commissioner for Patents


Washington, DC 20231

SIR: Please place the U.S. Patent and Trademark Office date stamp hereon to acknowledge receipt of the following:

1. Supplemental Information Disclosure Statement with Certificate of Mailing (3 pages)
2. Form PTO/SB/08A (1page)
3. Cited Reference (1)
4. Return Receipt Postcard



52105062.1/2018721-2187217053



Patent  
270/234  
18721-7053

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

) Group Art Unit: 2882

) Yoshihiro Takai, et al.

) Examiner: Not-Yet-Assigned

) Serial No.: 10/037,477

) Filed: January 2, 2002

For: METHOD AND APPARATUS FOR  
IRRADIATING A TARGET

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with 37 CFR § 1.97 and 1.98, and , the items identified in this Information Disclosure Statement (“IDS”) are brought to the attention of the Office. The items are listed on the attached form PTO/SB/08A (08-00). Copies of items 4 and 6 are enclosed for the convenience of the Examiner. Other references (items 1-3, 5, 7-8) are not enclosed since each item was submitted or cited in a parent application (Serial No. 09/178,383).

The items identified in this IDS may or may not be “material” pursuant to 37 CFR § 1.56. The submission thereof by Applicant is not to be construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR § 1.97(h)), or even qualifies as “prior art” under 35 USC § 102 with respect to this invention unless specifically designated by Applicant as such.

CERTIFICATE OF MAILING TRANSMISSION  
(37 C.F.R. §1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposit with the United States Postal Services on the date shown below with sufficient postage as “First Class Mail” to addressee in an envelope addressed to the Commissioner for Patents, Washington, D.C. 202031

3/17/03  
Date of deposit

Carolyn Tobias

Name of Person transmitting Paper

*Carolyn Tobias*

Signature of Person depositing Paper

**INFORMATION DISCLOSURE STATEMENT FILING PROVISION:**

This IDS is believed to be timely in that it is being submitted under 37 CFR § 1.97(b), that is (1) within three months of the filing date of the application, which is not a continued prosecution application filed under § 1.53(d) or (2) within three months of entry of the national stage as set forth in 37 CFR § 1.491; or (3) before the mailing of a first Office action on the merits; or (4) before the mailing of a first Office action after filing a request for continued examination under § 1.114. Thus, no fee is required.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and charge the fee due under 37 CFR § 1.17(p) to the deposit account referenced below.

However, if the undersigned is in error in this regard, Applicant respectfully requests that the Office consider this IDS as filed under 37 CFR § 1.97(c), if applicable, and a statement under 37 CFR § 1.97(e) is included below, thus no fee is required.

This IDS is being submitted under 37 CFR § 1.97(c), that is after mailing of a first Office action on the merits, but before a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311.

The fee due under 37 CFR § 1.17(p) is submitted herewith.

A statement under 37 CFR § 1.97(e) is included below, thus no fee is required. In the event that this IDS is not received before a Final Action or a Notice of Allowance, then Applicant respectfully requests that the Office consider the filing of these papers to be submitted under 37 CFR § 1.97(d) and charge the fee due under 37 CFR § 1.17(p) to the deposit account below.

This IDS is being submitted under 37 CFR § 1.97(d), that is after a Final Action under 37 CFR § 1.113 or a Notice of Allowance under 37 CFR § 1.311, but before payment of the issue fee. A statement under 37 CFR § 1.97(e) is included below. The fee due under 37 CFR § 1.17(p) is submitted herewith.

This IDS is being submitted under 37 CFR § 1.97(i); this IDS does not comply with either 37 CFR § 1.97 or § 1.98. Therefore it is requested to be placed in the file but not considered by the Patent Office. A statement under 37 CFR § 1.97(e) is included below.

Patent  
270/234  
18721-7053

**STATEMENT UNDER 37 CFR § 1.97(e):**

- Each item contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS.
- No item contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this statement after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this IDS.

**PAYMENT AND/OR AUTHORIZATION TO CHARGE FEES:**

- A check in the amount of \_\_\_\_\_ is enclosed for the above fee(s).
- The Commissioner is authorized to credit any overpayment and to charge any underpayment to Bingham McCutchen's Deposit Account No. 50-2518, referencing billing No. 18721-7053, for any fees required by the filing of these papers..

Respectfully submitted,  
BINGHAM McCUTCHEN LLP

By: Gerald Chan

Gerald Chan  
Reg. No. 51,541

BINGHAM McCUTCHEN LLP  
Three Embarcadero, Suite 1800  
San Francisco, CA 94111-4067  
(650) 849-4400

\*23639\*

23639

PATENT TRADEMARK OFFICE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-PTO

MAR 22 2004

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/037,477
Filing Date	January 2, 2002
First Named Inventor	Yoshihiro Takai, et al.
Art Unit	2882
Examiner Name	Not yet assigned
Attorney Docket No.	270/234; 18721-7053

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number – Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> – Number <sup>4</sup> – Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	
	1	Uematsu, Minoru, et al. "Daily Positioning Accuracy of Frameless Stereotactic Radiation Therapy with a Fusion of computed Tomography and Linear Accelerator (Focal) Unit: Evaluation of z-axis with a z-marker"; <i>Radiotherapy and Oncology</i> , Vol. 50, Issue 3, 1 March 1999, Pages 337-339.	

Examiner's Signature

Date Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.